Trials / Completed
CompletedNCT02402933
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
A Multiple Center, Open Label, Prospective Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.
Detailed description
This study is designed to evaluate the effectiveness of nasal glucagon (NG) administered under clinical use conditions in treating episodes of moderate or severe hypoglycemia in persons with T1D. This study also aims to assess the ease with which caregivers can administer the experimental medication in treatment of hypoglycemic events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nasal Glucagon | 3 mg nasal glucagon powder |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2015-03-30
- Last updated
- 2019-09-23
- Results posted
- 2017-06-26
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02402933. Inclusion in this directory is not an endorsement.